Science & Enterprise subscription

Follow us on Twitter

  • A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is ra… https://t.co/LFNVxych8d
    about 4 hours ago
  • New post on Science and Enterprise: New Allergy Biotech Launches, Raises $10M https://t.co/x5W0TwnCBu #Science #Business
    about 4 hours ago
  • Two companies and NIH are beginning a clinical trial of synthetic antibodies to both treat and prevent Covid-19 inf… https://t.co/LaUrUiRmhk
    about 23 hours ago
  • New post on Science and Enterprise: Trial Set for Covid-19 Antibodies in Long-Term Care https://t.co/tF0a7CDgGr #Science #Business
    about 23 hours ago
  • The numbers of vaccine candidates in development and clinical trials show modest but steady growth, now up to 157 a… https://t.co/AO2DxxTgF8
    about 1 day ago

Please share Science & Enterprise

New Allergy Biotech Launches, Raises $10M

Peanutes in shells

A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is raising $10 million in its first venture funding round. . . . → Read More: New Allergy Biotech Launches, Raises $10M

Four Ways Businesses Are Surviving Covid-19

Here are the examples that you can copy that are helping enterprises through this difficult period. . . . → Read More: Four Ways Businesses Are Surviving Covid-19

Neuro Disease Start-Up Raises $73M in Early Funds

Neuron

A company developing new therapies for neurodegenerative diseases officially began operations, staked to $73 million raised in its first venture round. . . . → Read More: Neuro Disease Start-Up Raises $73M in Early Funds

Synthetic Protein Maker Raises $91.3M in Venture Funds

Elastapure bottle

A company creating animal-free designer proteins for skin care products is raising more than $91 million in its second venture funding round. . . . → Read More: Synthetic Protein Maker Raises $91.3M in Venture Funds

Venture Funding Down in 2020, Life Sciences Stay Hot

Seed and angel investing

For the first half of 2020, venture investing declined compared to 2019, but life science and biotechnology investments continued growing for the year. . . . → Read More: Venture Funding Down in 2020, Life Sciences Stay Hot

Start-Up Developing Inside-Cell Delivery, Gains $28.5M

Vesicles

A new company spun-off from Harvard University is developing techniques for delivering advanced genetic and protein therapies directly inside cells. . . . → Read More: Start-Up Developing Inside-Cell Delivery, Gains $28.5M

Gene Therapy Production Company Opens, Raises $40M

Adeno-associated virus

A new enterprise developing and manufacturing gene therapies, both its own and for others, is underway, raising $40 million in venture funds. . . . → Read More: Gene Therapy Production Company Opens, Raises $40M

High-Capacity Brain Signal Reader Demonstrated

Brain circuits illustration

A brain-computer interface device is shown to record the highest volume of brain signals from lab animals and sheep, according to its developers. . . . → Read More: High-Capacity Brain Signal Reader Demonstrated

Investment Funds Named for Underserved Entrepreneurs

Investing monitor

A foundation project identified its first five investment funds providing capital for start-up businesses founded by people usually overlooked by venture investors. . . . → Read More: Investment Funds Named for Underserved Entrepreneurs

Start-Up Developing Coronavirus Antibodies, Raises $50M

Feeding bat

A new company is underway creating engineered antibodies to neutralize a range of coronaviruses, not just those causing Covid-19 infections. . . . → Read More: Start-Up Developing Coronavirus Antibodies, Raises $50M